Amphastar Pharmaceuticals, Inc. (AMPH) Director Stephen B. Shohet Sells 7,862 Shares
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Stephen B. Shohet sold 7,862 shares of the firm’s stock in a transaction dated Thursday, December 7th. The shares were sold at an average price of $18.34, for a total transaction of $144,189.08. Following the completion of the sale, the director now owns 31,978 shares of the company’s stock, valued at approximately $586,476.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Amphastar Pharmaceuticals, Inc. (AMPH) traded up $0.14 during mid-day trading on Friday, hitting $18.46. 108,118 shares of the stock were exchanged, compared to its average volume of 291,514. Amphastar Pharmaceuticals, Inc. has a 52 week low of $12.05 and a 52 week high of $21.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.86 and a current ratio of 3.08. The firm has a market cap of $842.73, a P/E ratio of 122.20 and a beta of 1.69.
Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, November 8th. The company reported $0.07 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.02 by $0.05. Amphastar Pharmaceuticals had a net margin of 0.12% and a return on equity of 2.30%. The company had revenue of $57.90 million during the quarter, compared to the consensus estimate of $57.23 million. During the same period last year, the firm earned $0.14 EPS. The company’s revenue for the quarter was down 9.8% on a year-over-year basis. equities research analysts expect that Amphastar Pharmaceuticals, Inc. will post -0.03 earnings per share for the current year.
A number of equities research analysts recently commented on the stock. Needham & Company LLC raised their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $23.00 and gave the company a “buy” rating in a research report on Friday, December 1st. BMO Capital Markets raised their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $17.00 and gave the company a “market perform” rating in a research report on Friday, November 10th. Raymond James Financial downgraded shares of Amphastar Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $18.00 price objective for the company. in a research report on Thursday, November 9th. Jefferies Group set a $19.00 price objective on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, October 29th. Finally, Zacks Investment Research downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Amphastar Pharmaceuticals has an average rating of “Hold” and a consensus target price of $20.86.
Amphastar Pharmaceuticals Company Profile
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.
Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.